Eli Lilly (LLY)

New York, NY – December 10, 2025 – The U.S. stock market is currently experiencing a robust rally, with major indices positioned tantalizingly close to their all-time highs. This bullish sentiment, culminating in a significant surge on December 10, 2025, is largely propelled by the Federal Reserve's recent interest rate cut

Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.

These stocks are down more than 20% this year, but they possess lots of upside potential over the long term.

Abivax shares rise on renewed takeover speculation tied to Eli Lilly following strong Phase 3 trial results.

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create 450 jobs.

The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier optimistic figures, a robust undercurrent of growth is emerging from the nation's manufacturing sector. This resurgence, largely driven by substantial

New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day

Eli Lilly is expanding its U.S. manufacturing footprint with a new Alabama facility that will add thousands of jobs.

A new revenue driver may be just ahead.

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical safe-haven for investors fleeing economic uncertainty and a strategic industrial metal indispensable to the burgeoning green and high-tech economies. With

Blockbuster drugs are a major driver of the growth of healthcare stocks.

Here are some things I think are more likely to happen in 2026 than the experts seem to believe.

Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated move, expected to be a 25-basis-point cut, is poised to reshape monetary policy landscapes, while persistent geopolitical tensions and the

After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.

JPMorgan Chase & Co. (NYSE: JPM), a titan of the financial industry and a significant component of the Dow Jones Industrial Average (DJIA), recently experienced a notable shift in market sentiment. Despite a year of robust financial performance characterized by surging earnings and revenue growth throughout 2024 and 2025, a cautious

It continues to be pounded by competition and challenges coming from numerous directions.

Market-based odds now show an 87% chance of a rate cut.

Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026.

This is no reason to panic.

Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors.